VESTAL POINT CAPITAL LP
Q3 2026 Form 13-F

NEW YORK, DELAWARE
CIK 0001974915 · CRD 325894 · SEC-registered investment adviser
$3.9B Reported Value Total

VESTAL POINT CAPITAL, LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $5,469,117,378, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $2.8B gross asset value
Hedge Fund: $2.8B
Source: Form ADV filed 2026-03-31
Reported value
$3.9B
Quarter over quarter
-13.2%
Holdings
63
Top-10 concentration
67.3%

Key People

Form ADV owners & control persons
Ryan Christopher Wilder
MANAGING PARTNER AND CHIEF INVESTMENT OFFICER
Ilko Latchezarov Menkov
PARTNER, COO AND CCO
Benjamin German Carroll
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $3.9B
Positions 63
Change in reported value -9.6%
New positions 15
Exited positions 20
Position turnover 42.2%
Top-10 concentration 67.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
63 $3.9B
Q2 2026 13F
Filed Aug 14, 2026
68 $4.3B
Q1 2026 13F
Filed May 15, 2026
90 $3.6B
Q4 2025 13F
Filed Feb 17, 2026
75 $2.9B
Q3 2025 13F
Filed Nov 14, 2025
80 $2.2B
Q2 2025 13F
Filed Aug 14, 2025
72 $1.9B
Q1 2025 13F
Filed May 15, 2025
63 $1.4B
Q4 2024 13F
Filed Feb 14, 2025
73 $1.7B
Q3 2024 13F
Filed Nov 14, 2024
67 $1.3B
Q2 2024 13F
Filed Aug 14, 2024
60 $1.3B
Q1 2024 13F
Filed May 14, 2024
58 $1.2B
Q4 2023 13F
Filed Feb 13, 2024
48 $944.0M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 ABVX Abivax SA $392.1M 10.13%
2 NBIX Neurocrine Biosciences Inc $354.6M 9.16%
3 BMRN BioMarin Pharmaceutical Inc $331.5M 8.56%
4 ARWR Arrowhead Pharmaceuticals Inc $315.1M 8.14%
5 INSM Insmed Inc $311.0M 8.04%
6 UTHR United Therapeutics Corp $257.4M 6.65%
7 ASND Ascendis Pharma A/S $168.6M 4.36%
8 NRIX Nurix Therapeutics Inc $166.6M 4.3%
9 TARS Tarsus Pharmaceuticals Inc $159.9M 4.13%
10 ELVN Enliven Therapeutics Inc $147.8M 3.82%
11 IRON Disc Medicine Inc $107.0M 2.77%
12 BCAX Bicara Therapeutics Inc $102.8M 2.66%
13 DYN Dyne Therapeutics Inc $99.9M 2.58%
14 IMTX Immatics NV $98.3M 2.54%
15 TSHA Taysha Gene Therapies Inc $87.9M 2.27%
16 GLUE Monte Rosa Therapeutics Inc $85.1M 2.2%
17 GMED Globus Medical Inc $68.5M 1.77%
18 CBIO Crescent Biopharma Inc $43.8M 1.13%
19 ZBH Zimmer Biomet Holdings Inc $42.2M 1.09%
20 TVTX Travere Therapeutics Inc $35.3M 0.91%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings